Literature DB >> 12509759

Therapeutic antibodies for human diseases at the dawn of the twenty-first century.

Ole Henrik Brekke1, Inger Sandlie.   

Abstract

Antibodies are highly specific, naturally evolved molecules that recognize and eliminate pathogenic and disease antigens. The past 30 years of antibody research have hinted at the promise of new versatile therapeutic agents to fight cancer, autoimmune diseases and infection. Technology development and the testing of new generations of antibody reagents have altered our view of how they might be used for prophylactic and therapeutic purposes. The therapeutic antibodies of today are genetically engineered molecules that are designed to ensure high specificity and functionality. Some antibodies are loaded with toxic modules, whereas others are designed to function naturally, depending on the therapeutic application. In this review, we discuss various aspects of antibodies that are relevant to their use as as therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12509759     DOI: 10.1038/nrd984

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  126 in total

1.  Chemically programmed monoclonal antibodies for cancer therapy: adaptor immunotherapy based on a covalent antibody catalyst.

Authors:  Christoph Rader; Subhash C Sinha; Mikhail Popkov; Richard A Lerner; Carlos F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-17       Impact factor: 11.205

2.  Use of fluorescence-detected sedimentation velocity to study high-affinity protein interactions.

Authors:  Sumit K Chaturvedi; Jia Ma; Huaying Zhao; Peter Schuck
Journal:  Nat Protoc       Date:  2017-08-03       Impact factor: 13.491

3.  Inhibition of foam cell formation using a soluble CD68-Fc fusion protein.

Authors:  Karin Daub; Dorothea Siegel-Axel; Tanja Schönberger; Christoph Leder; Peter Seizer; Karin Müller; Martin Schaller; Sandra Penz; Dagmar Menzel; Berthold Büchele; Andreas Bültmann; Götz Münch; Stephan Lindemann; Thomas Simmet; Meinrad Gawaz
Journal:  J Mol Med (Berl)       Date:  2010-05-08       Impact factor: 4.599

4.  Improving mass accuracy of high performance liquid chromatography/electrospray ionization time-of-flight mass spectrometry of intact antibodies.

Authors:  Himanshu S Gadgil; Gary D Pipes; Thomas M Dillon; Michael J Treuheit; Pavel V Bondarenko
Journal:  J Am Soc Mass Spectrom       Date:  2006-04-21       Impact factor: 3.109

Review 5.  Molecular targeting of angiogenesis for imaging and therapy.

Authors:  Simon S Brack; Ludger M Dinkelborg; Dario Neri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-08-05       Impact factor: 9.236

6.  Opalescent appearance of an IgG1 antibody at high concentrations and its relationship to noncovalent association.

Authors:  Muppalla Sukumar; Brandon L Doyle; Jessica L Combs; Allen H Pekar
Journal:  Pharm Res       Date:  2004-07       Impact factor: 4.200

7.  An innovative approach for the characterization of the isoforms of a monoclonal antibody product.

Authors:  Shanmuuga Sundaram; Alice Matathia; Jun Qian; Jingming Zhang; Ming-Ching Hsieh; Tun Liu; Richard Crowley; Babita Parekh; Qinwei Zhou
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

8.  An efficient method for variable region assembly in the construction of scFv phage display libraries using independent strand amplification.

Authors:  Pablo Sotelo; Noberto Collazo; Roberto Zuñiga; Matías Gutiérrez-González; Diego Catalán; Carolina Hager Ribeiro; Juan Carlos Aguillón; María Carmen Molina
Journal:  MAbs       Date:  2012-07-01       Impact factor: 5.857

9.  Cytokine binding by polysaccharide-antibody conjugates.

Authors:  Liang Tso Sun; Kyle S Buchholz; Michael T Lotze; Newell R Washburn
Journal:  Mol Pharm       Date:  2010-09-01       Impact factor: 4.939

10.  Rapid quantitative analysis of monoclonal antibody heavy and light chain charge heterogeneity.

Authors:  Ram P Vanam; Michael A Schneider; Michael S Marlow
Journal:  MAbs       Date:  2015-08-25       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.